Celcuity

Celcuity Treasury Stock

The Treasury Stock of Celcuity (CELC) as of Nov 11, 2026 is 549.40 M USD. In the previous year, Treasury Stock was 387.44 M USD — a change of 41.80% (higher).

Treasury Stock

549.40 MUSD

YoY

41.80%

Last updated:

Treasury Stock of Celcuity is 2025 549.40 M USD. Treasury Stock of Celcuity was 2024 387.44 M USD. It decreases by 41.80% higher compared to the previous year.

The Celcuity Treasury Stock history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Treasury Stock
Date
Treasury Stock
Jan 1, 2018
35.31 M USD
Jan 1, 2019
36.13 M USD
Jan 1, 2020
38.01 M USD
Jan 1, 2021
124.62 M USD
Jan 1, 2022
230.05 M USD
Jan 1, 2023
299.82 M USD
Jan 1, 2024
387.44 M USD
Jan 1, 2025
549.40 M USD
The Celcuity Treasury Stock history
YEARTreasury StockYoY
549.40 MUSD+41.80%
387.44 MUSD+29.22%
299.82 MUSD+30.33%
230.05 MUSD+84.59%
124.62 MUSD+227.84%
38.01 MUSD+5.20%
36.13 MUSD+2.34%
35.31 MUSD+5.75%
33.39 MUSD+139.58%
13.94 MUSD+38.93%
10.03 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Celcuity Stock analysis

What does Celcuity do? Celcuity Inc is a biotechnology company founded by Brian Sullivan in 2012. The company is headquartered in Minneapolis, USA. The business model of Celcuity is based on researching and developing new diagnostic and treatment methods for various types of cancer. The company utilizes a proprietary technology platform called CELx, which enables the analysis of cancer cell signaling pathways and the development of individualized treatment strategies. Celcuity specializes in the development of diagnostics and personalized therapies based on individual cancer cell signaling pathways. The company operates in two divisions: 1. Diagnostics division: Celcuity's diagnostics division focuses on identifying new cancer markers and biomarkers for early detection of cancer and the development of individualized treatment strategies. 2. Therapy division: Celcuity's therapy division specializes in the development of personalized therapies based on individual cancer cell signaling pathways. Celcuity currently offers two products based on the CELx technology platform: 1. CELx HUB: CELx HUB is a cloud-based software that allows doctors and researchers to analyze cancer samples and develop individualized treatment strategies. 2. CELx TIL: CELx TIL is a diagnostic tool that measures the presence of tumor cells in the immune system of cancer patients. In summary, Celcuity Inc is a leader in the field of personalized cancer therapy based on individual cancer cell signaling pathways. The company has found a niche in this growing market and has a unique technology platform that allows it to serve its customers effectively. With its products and services, Celcuity is helping to revolutionize cancer treatment and improve the quality of life for cancer patients worldwide. Celcuity is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Celcuity stock

Treasury Stock of Celcuity is 549.40 M USD in 2025.

Treasury Stock of Celcuity changed from 387.44 M USD to 549.40 M USD, representing a 41.80% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Treasury Stock Celcuity since 2006 – with annual values, charts, and detailed analysis.

Treasury stock represents shares that were repurchased by the company. It reduces shareholders' equity and outstanding share count.

Treasury Stock's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Treasury Stock's Celcuity historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Celcuity

All Key Metrics — Celcuity